Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus

Model scores of the 29,894 trials active now.

Model score 11% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 9% of the time (803 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-05-15. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Drug's FAERS reports marked serious: 7.5% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 2219 (raises risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Sponsor's past termination rate: 5.8% (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 0.1% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: carcinomacellsubjects withrandomizationin subjects
  Phrases that lowered it: type diabetesefficacymellitusmetforminsingle dose
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: 80 (raises risk) · Who can join
• Blinding: double (raises risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area
• Disease area, metabolic: Yes (lowers risk) · Disease area
• Drug's FAERS reports before start: 2944 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects NCT02660736 · started 2016 · scored riskier than 1% of active trials completed
• Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus NCT02229227 · started 2014 · scored riskier than 24% of active trials completed
• A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine NCT00976391 · started 2009 · scored riskier than 30% of active trials completed
• Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus NCT02284009 · started 2014 · scored riskier than 47% of active trials completed
• Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s) NCT03798054 · started 2019 · scored riskier than 7% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.